A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Inclusion Criteria:

   - Body weight of ≥ 40 kg at Baseline Visit for participants ≥ 12 and < 18 years of age

   - Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years prior to
   Baseline Visit and subject meets Hanifin and Rajka criteria.

   - Active moderate to severe atopic dermatitis defined by Eczema Area and Severity Index
   (EASI) ≥ 16, validated Investigator's Global Assessment (vIGA) ≥ 3, ≥ 10% of body
   surface area (BSA) with AD involvement, and weekly average of daily Worst Pruritus
   numerical rating scale (NRS) ≥ 4.

   - Subject has applied a topical emollient (moisturizer) twice daily for at least 7 days
   before the Baseline Visit.

   - Documented history of inadequate response to topical corticosteroids or topical
   calcineurin inhibitor OR documented systemic treatment for AD within 6 months prior to
   Baseline Visit

Exclusion Criteria:

   - Prior exposure to any Janus kinase (JAK) inhibitor

   - Unable or unwilling to discontinue current atopic dermatitis (AD) treatments prior to
   the study

   - Requirement of prohibited medications during the study

   - Other active skin diseases or skin infections requiring systemic treatment or would
   interfere with appropriate assessment of atopic dermatitis lesions

   - Female subject who is pregnant, breastfeeding, or considering pregnancy during the
   study